Switzerland's Roche agrees to acquire US-based PathAI
- May 8
- 1 min read
REUTERS — Swiss pharmaceutical giant Roche (ROPC.S) said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus further milestone payments of up to $300 million.
The acquisition builds on a five-year partnership between Roche and PathAI that was scaled up in 2024 to include the development of AI-enabled companion diagnostic algorithms.
Read the full story | REUTERS
